STATESVILLE, N.C. , June 24 /PRNewswire-FirstCall/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU) today reported results for its fiscal year and fourth quarter ended April 30, 2008 .

Net earnings for the year increased 104% to $3,134,000 , or $1.23 per diluted share, up from net earnings of $1,540,000 , or $0.62 per diluted share, in the prior year. Earnings benefited from a strong performance from the Company's domestic operations, improved profit margins, and continued growth of its international operations.

Sales for the year increased 9.9% to $89,510,000 , up from sales of $81,441,000 in the prior year. Incoming orders were strong throughout the year, both domestic and international. The order backlog was a record year-end level of $58.7 million at April 30, 2008 , up from $51.1 million at April 30, 2007 . Sales from domestic operations increased to $73,768,000 , up 10.8% from the prior year. Sales from international operations increased to $15,742,000 , up 6.0% from the prior year.

'We made progress in a number of important areas in fiscal year 2008,' said William A. Shumaker, President and Chief Executive Officer. 'We are particularly pleased with the performance of our domestic operations, which were successful in increasing sales over all major product lines, building up our order backlog to record levels, and reducing manufacturing costs. Our international operations continued to execute well, with continued growth in sales, earnings, and order backlog during the year. In addition to operational accomplishments, our Statesville operations successfully moved to a new comprehensive ERP business management system late in the fourth quarter, and we successfully completed our project to become Sarbanes-Oxley Section 404 compliant.

'Our continued successes in fiscal year 2008 have made us a much stronger Company and keeps us on a solid track for long-term success and profitability,' continued Mr. Shumaker. 'Looking toward fiscal year 2009, we begin the year with a strong order backlog, good operating momentum, and healthy marketplaces for our products, both domestically and internationally. Like many businesses, we are challenged these days with extraordinary escalations in prices of raw materials, particularly steel and epoxy resin, energy, and transportation costs. We are aggressively pursuing strategies to minimize these increases.'

The Company's financial condition further strengthened during the year. Working capital increased to $15.9 million at April 30, 2008 , up from $12.3 million at the end of the prior year. Cash on hand at the end of the year increased to $4.3 million , up from $2.6 million at the end of the prior year. Bank borrowings and capital lease obligations were $5.0 million at year-end, as compared to $4.3 million at the end of the prior year, and the debt-to-equity ratio was .19-to-1 at year-end, as compared to .18-to-1 at the end of the prior year.

Net earnings for the fourth quarter were $446,000 , or $.17 per diluted share, as compared to net earnings of $517,000 , or $.21 per diluted share, in the prior year. Sales for the fourth quarter were $22,116,000 , down slightly from sales of $22,721,000 in the same quarter of the prior year. Sales from domestic operations for the quarter were flat with the same quarter of the prior year, while sales from international operations declined slightly. Shipments and earnings were unfavorably impacted by inefficiencies and expenses associated with the Company's conversion during the quarter to a new comprehensive ERP system which incorporated all of the Company's business management systems.

As recently announced, the Company increased its quarterly cash dividend to eight cents per outstanding share, up from seven cents per share declared in the previous quarter.

Kewaunee Scientific Corporation is a recognized leader in the design, manufacture, and installation of scientific and technical furniture. The Company's corporate headquarters and domestic manufacturing facilities are located in Statesville, North Carolina . The Company also has subsidiaries in Singapore and Bangalore, India that serve the Asian and Middle East markets. Kewaunee Scientific's website is located at http://www.kewaunee.com .

Certain statements in this release constitute 'forward-looking' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company's operations, markets, products, services, and prices.



                    Consolidated Statements of Operations
                    (in thousands, except per share data)

                              Three Months Ended         Year Ended
                                   April 30               April 30
                                2008      2007          2008     2007

                                 (Unaudited)

    Net sales                $22,116   $22,721       $89,510  $81,441

    Cost of products sold     17,579    18,467        70,338   66,355
    Gross profit               4,537     4,254        19,172   15,086

    Operating expenses         3,748     3,363        13,559   11,728
    Operating earnings           789       891         5,613    3,358

    Other income                  49        20            47       53
    Interest expense               8     (146)         (294)    (670)

    Earnings before
     income taxes                846       765         5,366    2,741
    Income tax expense           342       289         1,733      902

    Earnings before minority
     interests                   504       476         3,633    1,839
    Minority interests in
     subsidiaries                (58)       41         (499)    (299)
    Net earnings                $446      $517        $3,134   $1,540

    Net earnings per share

              Basic            $0.17     $0.21         $1.24    $0.62

              Diluted          $0.17     $0.21         $1.23    $0.62
    Weighted average number
     of common shares
     outstanding
     (in thousands)
              Basic            2,551     2,494         2,530    2,493
              Diluted          2,577     2,502         2,557    2,495



                    Condensed Consolidated Balance Sheets
                                (in thousands)

                                                 April 30     April 30
    Assets                                         2008         2007

    Cash and cash equivalents                     $3,784       $2,231
    Restricted cash                                  480          372
    Receivables, less allowances                  20,561       19,061
    Inventories                                    6,984        5,869
    Prepaid expenses and other current assets      1,847          981
       Total current assets                       33,656       28,514
    Net property, plant and equipment             11,825       11,255
    Other assets                                   5,599        5,471
    Total Assets                                 $51,080      $45,240

    Liabilities and Stockholders' Equity
    Short-term borrowings                         $4,551       $3,489
    Current obligations under capital leases         323          360
    Accounts payable                               8,929        8,437
    Other current liabilities                      3,933        3,897
       Total current liabilities                  17,736       16,183
    Other non-current liabilities                  6,397        5,009
    Total stockholders' equity                    26,947       24,048
    Total Liabilities and Stockholders' Equity   $51,080      $45,240

    Contact: D. Michael Parker
             704/871-3290

SOURCE Kewaunee Scientific Corporation